Table 6.

Additional areas of interest within mesothelioma immunotherapy

Outstanding areas of interest for immunotherapy in MPM
1	Can we combine Tumor-Treating Fields (TTF) with checkpoint inhibitors?
2	How can we best stratify patients to checkpoint inhibitors?
3	Is there any utility for the use of PD-L1 expression as a biomarker to direct therapy?
4	Can we epigenetically prime MPM for checkpoint inhibitor therapy?
5	Can we use BAP1 status in immunotherapy of MPM?
6	Would targeting Toll Like Receptors (TLRs) along with checkpoint inhibitors prove beneficial?
7	What is the best way to monitor response to checkpoint inhibitors?
8	Is the cost prohibitive for the use of checkpoint inhibitors in the second-line/salvage setting?